Date:5/4/2009

99,728 99,728 Other liability 17,778 23,062 ---------- ---------- TOTAL LIABILITIES 1,092,579 807,281 ---------- ---------- STOCKHOLDERS' EQUITY: Preferred stock, $0.01 par value; authorized 5,000,000 shares, no shares issued -- -- Common stock, $0.01 par value; authorized 100,000,000 shares, issued and outstanding 19,511,199 and 18,375,117, respectively 195,112 183,751 Capital in excess of par 41,020,987 39,874,958 Deficit accumulated during the development stage (34,360,254) (30,223,030) ---------- ---------- TOTAL STOCKHOLDERS' EQUITY 6,855,845 9,835,679 ---------- ---------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $7,948,424 $10,642,960 ========== ==========

'/>"/>

SOURCE Senesco Technologies, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
2. Senesco and Harris Moran Mutually Agree to Terminate Development and License Agreement Due to Restructuring
3. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
6. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
7. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
8. Senesco Technologies to Present at BIO 2008 Business Forum
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results